Saad Z. Usmani, MD, MBA, FACP, on Intriguing Data for High-Risk Multiple Myeloma at 2021 ASCO

Video

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

In a conversation with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, detailed data from a handful of trials presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on patients with high-risk multiple myeloma and the need for further research into this area.

Transcription:

I was encouraged to see abstracts that are focusing on the high-risk patients in the newly diagnosed setting. There is the UK myeloma group study that is looking at ultra–high-risk and plasma cell leukemia [disease]. There is high-risk data being reported from the FORTE randomized, phase 2 trial (NCT02203643) experience. I do feel that high-risk [disease] is a very specific biologic subgroup that needs to be studied separately. I’m very encouraged by that [and] that we’re starting to see data in that particular subgroup.

The other area of interest at ASCO this year is updates from the bispecific antibodies, particularly targeting [B-cell maturation antigen], but also GPRC5D. Those data continue to look better and better. [It’s] very encouraging to see a new bispecific antibody [from] Pfizer which has a subcutaneous formulation showing good early responses in a refractory myeloma patient population. Those 2 would be my key or important ASCO abstract takeaways, besides the cellular therapy data, the high-risk subset being evaluated and then the new data in the bispecifics.

Reference

1. Berdeja JG, Krishnan AY, Oriol A, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). 10.1200/JCO.2021.39.15_suppl.8008 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 8008-8008.

2. Gay F, Mina R, Rota-Scalabrini D, et al. Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. J Clin Oncol 39, 2021 (suppl 15; abstr 8002). doi: 10.1200/JCO.2021.39.15_suppl.8002.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content